M.R. García-Campelo - Medical Oncology Department, CHUAC - Complexo Hospitalario Universitario A Coruña

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 18 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

LBA51 Circulating Tumor DNA (ctdna) Dynamics and Treatment Responses in Chemotherapy-Ineligible Patients (pts) with Unresectable Stage III NSCLC from the Phase II DUART Trial

A.R. Filippi,M.R. Garcia-Campelo,J-B. Paoli,D.M. Kowalski,C. Bennati, P. Borghetti,D.L. Cortinovis, A. Delmonte, C. Genova, R.M. Mroz,S. Nawrocki,I. Toledano, G. Tonini, R. Stewart, Z. Zhu, G. Wetherill,N.E. Georgoulia,I. Diaz Perez, R. Dziadziuszko

Annals of Oncology (2024)

引用0浏览0引用

1440P Final Top-Line Results of the BGBC008 Phase II, Multicenter Study of Bemcentinib and Pembrolizumab (bem+pembro) in Second-Line (2L) Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer (NSCLC) (NCT03184571)

E. Felip,M.G. Krebs,E. Carcereny,K.B. Smeland,E. Arriola,C. Llacer Perez,J. Thompson,L. Paz-Ares,M. Domine Gomez, J.R. Olivares,N. Vinolas Segarra,M.R. García-Campelo,A.L.O. Ortega Granados,M. Chisamore,D. Micklem,N. McCracken, A. Rayford, C. Oliva, C. Gorcea-Carson,J. Spicer

Annals of oncology（2023）

引用0浏览0引用

Amivantamab plus chemotherapy (with or without lazertinib) vs chemotherapy in EGFR-mutated advanced NSCLC after progression on osimertinib: MARIPOSA-2, a phase III, global, randomized, controlled trial

A. Passaro,B. C. Cho, Y. Wang,B. Melosky,R. Califano, S-H. Lee,N. Girard,K. L. Reckamp, T. Takahashi,E. Felip,R. D. Gentzler,S. Popat,W. Nassib William, T. Sun, S. Shah,B. Diorio,R. E. Knoblauch,J. M. Bauml,M. R. Garcia-Campelo, J. Wang

ANNALS OF ONCOLOGY (2023): S1307-S1307

引用0浏览0引用

Durvalumab after radiotherapy (RT) in patients with unresectable stage III NSCLC ineligible for chemotherapy (CT): Primary results from the DUART study

A. R. R. Filippi,M. R. Garcia-Campelo, J. B. Paoli,D. Kowalski,C. Bennati,P. Borghetti,D. L. Cortinovis,A. Delmonte,C. Genova,S. Van Hulst, R. Mroz,S. Nawrocki,I. Toledano, G. Tonini,I. Diaz Perez,N. E. Georgoulia,K. Foroutanpour,R. Dziadziuszko

ANNALS OF ONCOLOGY (2023): S1302-S1302

引用0浏览0引用

1476P Outcomes to First-Line Pembrolizumab in Patients with Advanced NSCLC and High PD-L1 Expression: A Spanish Multicentric Study

A. Piedra,S. Martinez Recio,A. Hernandez Gonzalez,M.T. Moran Bueno,E. Arriola, J. Recuero-Borau,M. Cobo Dols,P. Cordeiro González,J. Mosquera Martinez,M.R. García-Campelo,A. Calles Blanco,R.M. Alvarez, M. Zapata García,M.D. Isla Casado,A. Callejo Perez,P. Iranzo Gomez,A. Barba Joaquín,I.G. Sullivan, E. Felip,M. Majem

Annals of oncology (2023): S835-S836

引用0浏览0引用

P1.27-07 BRAF Mutations Identify Non-small-Cell Lung Cancer Patients Who Benefit from Neoadjuvant Chemo-Immunotherapy

JOURNAL OF THORACIC ONCOLOGYno. 11 (2023): S286-S286

引用0浏览0引用

LBA62 Durvalumab after Radiotherapy (RT) in Patients with Unresectable Stage III NSCLC Ineligible for Chemotherapy (CT): Primary Results from the DUART Study

A.R.R. Filippi,M.R. García-Campelo,J Paoli, Diane Kowalski,C. Bennati,P. Borghetti,Diego Cortinovis,Angelo Delmonte,C. Genova, S. van Hülst, R. Mroz,Sergiusz Nawrocki, I. Toledano, G. Tonini,I. Diaz Perez,N.E. Georgoulia,K. Foroutanpour,Rafał Dziadziuszko

Annals of oncology (2023): S1302-S1302

引用0浏览0引用

Final top-line results of the BGBC008 phase II, multicenter study of bemcentinib and pembrolizumab (bem plus pembro) in second-line (2L) advanced non-squamous (NS) non-small cell lung cancer (NSCLC) (NCT03184571)

E. Felip,M. G. Krebs,E. Carcereny,K. B. Smeland,E. Arriola,C. Llacer Perez, J. Thompson,L. Paz-Ares,M. Domine Gomez, J. R. Olivares,N. Vinolas Segarra,M. R. Garcia-Campelo,A. L. O. Ortega Granados,M. Chisamore,D. Micklem,N. McCracken, A. Rayford, C. Oliva, C. Gorcea-Carson,J. Spicer

ANNALS OF ONCOLOGY (2023)

引用0浏览0引用

3P Exploratory Efficacy Analysis by Smoking Status in PD-L1 High Patients in the Phase III, Non-Small Cell Lung Cancer (NSCLC) IMpower110 Study

L. Paz-Ares,M.R. García-Campelo,M.D. Isla Casado,E. Carcereny,D. Rodriguez Abreu,J.J. Garcia Gonzalez,D. Perez Parente, N. Gonzalez Mancha, E. Vilas,P. Ruiz Gracia, A. Greco,D.R. Spigel,F. de Marinis,J. Jassem

Immuno-Oncology and Technology (2023): 100474

引用0浏览0引用

12P Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers Associated with Long-Term Benefit with Chemoimmunotherapy in Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

M. Peressini, C. Martí Cubells,V. Gutierrez Calderon,B. Massuti Sureda,M. Majem,M.R. García-Campelo,P. Diz Tain,M.D. Isla Casado,A. Moreno Paul, F.J. Garcia Navalon, M. Molero,V. Adradas,E. Conde Gallego,L. Paz-Ares,J. Zugazagoitia

Immuno-Oncology and Technology (2023): 100482

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn